drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01076 | DB05773 | 700 | 1,047 | [
"DDInter133",
"DDInter1848"
] | Atorvastatin | Trastuzumab emtansine | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
700,
24,
1047
]
],
[
[
700,
24,
375
],
[
375,
63,
1047
]
],
[
[
700,
63,
458
],
[
458,
24,
1047
]
],
[
[
700,
24,
14
],
[
14,
24... | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab... | Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Atorvastatin may cause a moderate interaction that could exacerbate diseases when t... |
DB00087 | DB14443 | 599 | 987 | [
"DDInter41",
"DDInter1931"
] | Alemtuzumab | Vibrio cholerae CVD 103-HgR strain live antigen | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
599,
24,
987
]
],
[
[
599,
24,
1480
],
[
1480,
24,
987
]
],
[
[
599,
63,
1172
],
[
1172,
24,
987
]
],
[
[
599,
25,
1510
],
[
1510,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Alemtuzumab may cause a moderate interaction that could exacerbate diseases wh... |
DB00848 | DB06372 | 281 | 259 | [
"DDInter1044",
"DDInter1594"
] | Levamisole | Rilonacept | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
281,
24,
259
]
],
[
[
281,
24,
651
],
[
651,
24,
259
]
],
[
[
281,
24,
1367
],
[
1367,
63,
259
]
],
[
[
281,
63,
208
],
[
208,
2... | [
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
],
[
... | Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vacci... |
DB00990 | DB12267 | 1,547 | 1,476 | [
"DDInter705",
"DDInter233"
] | Exemestane | Brigatinib | Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1547,
24,
1476
]
],
[
[
1547,
63,
629
],
[
629,
24,
1476
]
],
[
[
1547,
24,
1598
],
[
1598,
63,
1476
]
],
[
[
1547,
24,
35
],
[
35,
... | [
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Exemestane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
... | Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Exemestane may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazeme... |
DB00529 | DB11113 | 789 | 657 | [
"DDInter779",
"DDInter307"
] | Foscarnet | Castor oil | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
789,
24,
657
]
],
[
[
789,
24,
927
],
[
927,
63,
657
]
],
[
[
789,
24,
1491
],
[
1491,
24,
657
]
],
[
[
789,
25,
985
],
[
985,
2... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
... | Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midos... |
DB00909 | DB12267 | 306 | 1,476 | [
"DDInter1971",
"DDInter233"
] | Zonisamide | Brigatinib | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
306,
24,
1476
]
],
[
[
306,
63,
629
],
[
629,
24,
1476
]
],
[
[
306,
24,
918
],
[
918,
24,
1476
]
],
[
[
306,
24,
982
],
[
982,
... | [
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
... | Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalu... |
DB01344 | DB09322 | 1,231 | 1,114 | [
"DDInter1830",
"DDInter1966"
] | Tolevamer | Zinc sulfate | Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels. It may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. It is also an effective topical microbicide and spermicide, inhibiting the genital transfection of, among others, H... | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Moderate | 1 | [
[
[
1231,
24,
1114
]
],
[
[
1231,
63,
251
],
[
251,
23,
1114
]
],
[
[
1231,
24,
260
],
[
260,
62,
1114
]
],
[
[
1231,
24,
1596
],
[
1596,
... | [
[
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[... | Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Ferrous sulfate a... |
DB00078 | DB00285 | 1,172 | 1,100 | [
"DDInter898",
"DDInter1927"
] | Ibritumomab tiuxetan | Venlafaxine | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Moderate | 1 | [
[
[
1172,
24,
1100
]
],
[
[
1172,
24,
643
],
[
643,
40,
1100
]
],
[
[
1172,
64,
366
],
[
366,
24,
1100
]
],
[
[
1172,
25,
126
],
[
126,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desven... | Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine (Compound) resembles Venlafaxine (Compound)
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate inte... |
DB00067 | DB00687 | 317 | 870 | [
"DDInter1921",
"DDInter747"
] | Vasopressin | Fludrocortisone | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
317,
24,
870
]
],
[
[
317,
24,
688
],
[
688,
62,
870
]
],
[
[
317,
24,
392
],
[
392,
63,
870
]
],
[
[
317,
25,
478
],
[
478,
63,... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
... | Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Fludrocortisone
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and La... |
DB00575 | DB00635 | 1,020 | 1,573 | [
"DDInter412",
"DDInter1515"
] | Clonidine | Prednisone | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
1020,
24,
1573
]
],
[
[
1020,
24,
175
],
[
175,
40,
1573
]
],
[
[
1020,
63,
251
],
[
251,
1,
1573
]
],
[
[
1020,
24,
167
],
[
167,
... | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
... | Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone (... |
DB01042 | DB10989 | 1,307 | 496 | [
"DDInter1144",
"DDInter858"
] | Melphalan | Hepatitis A Vaccine | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
1307,
24,
496
]
],
[
[
1307,
24,
4
],
[
4,
24,
496
]
],
[
[
1307,
63,
147
],
[
147,
24,
496
]
],
[
[
1307,
24,
738
],
[
738,
63,... | [
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesucc... | Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Melphalan may cause a moderate interaction that could exacerbate diseases ... |
DB00860 | DB06636 | 891 | 1,623 | [
"DDInter1513",
"DDInter980"
] | Prednisolone | Isavuconazonium | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
891,
24,
1623
]
],
[
[
891,
63,
1419
],
[
1419,
24,
1623
]
],
[
[
891,
40,
167
],
[
167,
24,
1623
]
],
[
[
891,
24,
1213
],
[
1213,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Prednisolone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interacti... |
DB01142 | DB01176 | 1,264 | 537 | [
"DDInter593",
"DDInter453"
] | Doxepin | Cyclizine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
1264,
24,
537
]
],
[
[
1264,
24,
1511
],
[
1511,
63,
537
]
],
[
[
1264,
40,
11244
],
[
11244,
1,
537
]
],
[
[
1264,
63,
1242
],
[
1242... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"M... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Doxepin (Compound) resembles Pheniramine (Compound) and Pheniramine (Compound) resembles Cyclizine (Compound)
Doxe... |
DB00697 | DB01211 | 876 | 609 | [
"DDInter1821",
"DDInter393"
] | Tizanidine | Clarithromycin | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
876,
24,
609
]
],
[
[
876,
6,
7950
],
[
7950,
45,
609
]
],
[
[
876,
18,
9429
],
[
9429,
57,
609
]
],
[
[
876,
21,
28759
],
[
28759,
... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Tizanidine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compoun... | Tizanidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Clarithromycin (Compound)
Tizanidine (Compound) downregulates CNDP2 (Gene) and CNDP2 (Gene) is downregulated by Clarithromycin (Compound)
Tizanidine (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Eff... |
DB00562 | DB01276 | 1,014 | 123 | [
"DDInter188",
"DDInter706"
] | Benzthiazide | Exenatide | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1014,
24,
123
]
],
[
[
1014,
24,
708
],
[
708,
63,
123
]
],
[
[
1014,
24,
1573
],
[
1573,
24,
123
]
],
[
[
1014,
1,
323
],
[
323,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
],
... | Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Prednisone a... |
DB00581 | DB14881 | 355 | 180 | [
"DDInter1018",
"DDInter1329"
] | Lactulose | Oliceridine | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
355,
24,
180
]
],
[
[
355,
24,
124
],
[
124,
24,
180
]
],
[
[
355,
63,
618
],
[
618,
24,
180
]
],
[
[
355,
23,
286
],
[
286,
24,... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix ma... |
DB00008 | DB06273 | 491 | 980 | [
"DDInter1407",
"DDInter1824"
] | Peginterferon alfa-2a | Tocilizumab | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
491,
24,
980
]
],
[
[
491,
24,
139
],
[
139,
24,
980
]
],
[
[
491,
24,
110
],
[
110,
63,
980
]
],
[
[
491,
25,
1477
],
[
1477,
2... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zido... | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB06702 | DB08881 | 573 | 868 | [
"DDInter731",
"DDInter1925"
] | Fesoterodine | Vemurafenib | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
573,
24,
868
]
],
[
[
573,
6,
8374
],
[
8374,
45,
868
]
],
[
[
573,
21,
28847
],
[
28847,
60,
868
]
],
[
[
573,
40,
211
],
[
211,
... | [
[
[
"Fesoterodine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Fesoterodine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Fesoterodine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Fesoterodine (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Fesoterodine (Compound) resembles Tolterodine (Compound) and Tolterodine may cause a minor interac... |
DB00619 | DB08912 | 1,419 | 1,040 | [
"DDInter909",
"DDInter462"
] | Imatinib | Dabrafenib | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
1419,
24,
1040
]
],
[
[
1419,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
1419,
6,
4779
],
[
4779,
46,
1040
]
],
[
[
1419,
18,
6448
],
[
6448... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Imatinib",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Imatinib (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Imatinib (Compound) binds DDR1 (Gene) and DDR1 (Gene) is upregulated by Dabrafenib (Compound)
Imatinib (Compound) downregulates CTSD (Gene) and CTSD (Gene) is upregulated by Dabrafenib (Compound)
Imatinib (Compound) upregulates ME... |
DB00655 | DB01142 | 559 | 1,264 | [
"DDInter682",
"DDInter593"
] | Estrone | Doxepin | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Minor | 0 | [
[
[
559,
23,
1264
]
],
[
[
559,
6,
4973
],
[
4973,
45,
1264
]
],
[
[
559,
21,
29134
],
[
29134,
60,
1264
]
],
[
[
559,
40,
1438
],
[
1438,... | [
[
[
"Estrone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxepin"
]
],
[
[
"Estrone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Doxep... | Estrone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxepin (Compound)
Estrone (Compound) causes Flatulence (Side Effect) and Flatulence (Side Effect) is caused by Doxepin (Compound)
Estrone (Compound) resembles Estradiol (Compound) and Estradiol may cause a minor interaction that can limit clinical effe... |
DB00444 | DB06643 | 63 | 1,136 | [
"DDInter1765",
"DDInter500"
] | Teniposide | Denosumab | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
63,
24,
1136
]
],
[
[
63,
24,
1213
],
[
1213,
24,
1136
]
],
[
[
63,
24,
1480
],
[
1480,
63,
1136
]
],
[
[
63,
63,
168
],
[
168,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib ma... |
DB00843 | DB14723 | 479 | 159 | [
"DDInter583",
"DDInter1026"
] | Donepezil | Larotrectinib | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Minor | 0 | [
[
[
479,
23,
159
]
],
[
[
479,
23,
741
],
[
741,
24,
159
]
],
[
[
479,
24,
98
],
[
98,
24,
159
]
],
[
[
479,
62,
597
],
[
597,
24,
... | [
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rolapitant"
],
[
... | Donepezil may cause a minor interaction that can limit clinical effects when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem ... |
DB06717 | DB12500 | 875 | 283 | [
"DDInter778",
"DDInter714"
] | Fosaprepitant | Fedratinib | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
875,
24,
283
]
],
[
[
875,
23,
466
],
[
466,
62,
283
]
],
[
[
875,
24,
351
],
[
351,
23,
283
]
],
[
[
875,
63,
1419
],
[
1419,
2... | [
[
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosaprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
... | Fosaprepitant may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and ... |
DB10989 | DB14004 | 496 | 398 | [
"DDInter858",
"DDInter1806"
] | Hepatitis A Vaccine | Tildrakizumab | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psorias... | Moderate | 1 | [
[
[
496,
24,
398
]
],
[
[
496,
63,
58
],
[
58,
24,
398
]
],
[
[
496,
24,
270
],
[
270,
24,
398
]
],
[
[
496,
63,
375
],
[
375,
25,
... | [
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tildrakizumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefac... | Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Tildrakizumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Oc... |
DB00590 | DB06691 | 1,433 | 849 | [
"DDInter592",
"DDInter1155"
] | Doxazosin | Mepyramine | Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfi... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1433,
24,
849
]
],
[
[
1433,
6,
12523
],
[
12523,
45,
849
]
],
[
[
1433,
24,
770
],
[
770,
24,
849
]
],
[
[
1433,
63,
1648
],
[
1648,
... | [
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Doxazosin",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Doxazosin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Doxazosin may caus... |
DB01069 | DB06723 | 401 | 115 | [
"DDInter1533",
"DDInter58"
] | Promethazine | Aluminum hydroxide | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Minor | 0 | [
[
[
401,
23,
115
]
],
[
[
401,
21,
29803
],
[
29803,
60,
115
]
],
[
[
401,
63,
1058
],
[
1058,
23,
115
]
],
[
[
401,
24,
1418
],
[
1418,
... | [
[
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Promethazine",
"{u} (Compound) causes {v} (Side Effect)",
"Venous thrombosis"
],
[
"Venous thrombosis",
... | Promethazine (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Aluminum hydroxide (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Moexipril and Moexipril may cause a minor interaction that can limit clinical effects... |
DB00549 | DB00745 | 522 | 307 | [
"DDInter1955",
"DDInter1236"
] | Zafirlukast | Modafinil | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Minor | 0 | [
[
[
522,
23,
307
]
],
[
[
522,
25,
704
],
[
704,
40,
307
]
],
[
[
522,
6,
7950
],
[
7950,
45,
307
]
],
[
[
522,
21,
28882
],
[
28882,
... | [
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Zafirlukast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fentanyl"
],
[
"Fentanyl",
... | Zafirlukast may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl (Compound) resembles Modafinil (Compound)
Zafirlukast (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Modafinil (Compound)
Zafirlukast (Compound) causes Body temperature increased (Side Effect) and Body tempe... |
DB00006 | DB06700 | 942 | 643 | [
"DDInter217",
"DDInter511"
] | Bivalirudin | Desvenlafaxine | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Moderate | 1 | [
[
[
942,
24,
643
]
],
[
[
942,
24,
1100
],
[
1100,
1,
643
]
],
[
[
942,
25,
292
],
[
292,
63,
643
]
],
[
[
942,
24,
1274
],
[
1274,
... | [
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
... | Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Bivalirudin may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may cause a moderate interaction that could exac... |
DB01324 | DB09082 | 178 | 659 | [
"DDInter1490",
"DDInter1934"
] | Polythiazide | Vilanterol | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
178,
24,
659
]
],
[
[
178,
63,
1220
],
[
1220,
23,
659
]
],
[
[
178,
24,
1296
],
[
1296,
63,
659
]
],
[
[
178,
1,
323
],
[
323,
... | [
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Insulin deglu... |
DB00108 | DB14711 | 1,066 | 779 | [
"DDInter1268",
"DDInter1680"
] | Natalizumab | Smallpox (Vaccinia) Vaccine, Live | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
1066,
25,
779
]
],
[
[
1066,
25,
1064
],
[
1064,
25,
779
]
],
[
[
1066,
64,
1560
],
[
1560,
25,
779
]
],
[
[
1066,
25,
994
],
[
994,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"... | Natalizumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Natalizumab may lead to a major life threatening interaction when taken with Pegaspargase and Pegaspargase may lead to... |
DB00026 | DB11988 | 1,184 | 270 | [
"DDInter94",
"DDInter1321"
] | Anakinra | Ocrelizumab | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
1184,
24,
270
]
],
[
[
1184,
23,
1193
],
[
1193,
23,
270
]
],
[
[
1184,
24,
1060
],
[
1060,
63,
270
]
],
[
[
1184,
24,
134
],
[
134,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Anakinra",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
... | Anakinra may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin a... |
DB06448 | DB12500 | 171 | 283 | [
"DDInter1087",
"DDInter714"
] | Lonafarnib | Fedratinib | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
171,
25,
283
]
],
[
[
171,
24,
466
],
[
466,
62,
283
]
],
[
[
171,
25,
351
],
[
351,
23,
283
]
],
[
[
171,
64,
1419
],
[
1419,
2... | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Daroluta... | Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Lonafarnib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may caus... |
DB00696 | DB09272 | 826 | 412 | [
"DDInter665",
"DDInter632"
] | Ergotamine | Eluxadoline | A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
826,
24,
412
]
],
[
[
826,
1,
1131
],
[
1131,
24,
412
]
],
[
[
826,
24,
1374
],
[
1374,
24,
412
]
],
[
[
826,
25,
384
],
[
384,
... | [
[
[
"Ergotamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Ergotamine",
"{u} (Compound) resembles {v} (Compound)",
"Methysergide"
],
[
"Methysergide",
"{u} may cause a mo... | Ergotamine (Compound) resembles Methysergide (Compound) and Methysergide may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction tha... |
DB01132 | DB01764 | 1,130 | 805 | [
"DDInter1472",
"DDInter469"
] | Pioglitazone | Dalfopristin | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Moderate | 1 | [
[
[
1130,
24,
805
]
],
[
[
1130,
6,
8374
],
[
8374,
45,
805
]
],
[
[
1130,
63,
222
],
[
222,
23,
805
]
],
[
[
1130,
24,
384
],
[
384,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Pioglitazone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Pioglitazone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Dalfopristin
Pioglitazo... |
DB00655 | DB08912 | 559 | 1,040 | [
"DDInter682",
"DDInter462"
] | Estrone | Dabrafenib | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
559,
24,
1040
]
],
[
[
559,
6,
4973
],
[
4973,
45,
1040
]
],
[
[
559,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
559,
63,
1101
],
[
1101,... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Estrone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"... | Estrone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dabrafenib (Compound)
Estrone (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexar... |
DB08901 | DB11095 | 1,468 | 235 | [
"DDInter1492",
"DDInter505"
] | Ponatinib | Desirudin | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Desirudin is a direct inhibitor of human thrombin. It has a protein structure that is similar to that of hirudin, the naturally occurring anticoagulant present in the peripharyngeal glands in the medicinal leech, Hirudo medicinalis. Hirudin is a single polypeptide chain of 65 amino acids residues and contains three dis... | Major | 2 | [
[
[
1468,
25,
235
]
],
[
[
1468,
63,
1100
],
[
1100,
24,
235
]
],
[
[
1468,
64,
578
],
[
578,
24,
235
]
],
[
[
1468,
24,
738
],
[
738,
... | [
[
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine"... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Desirudin
Ponatinib may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a... |
DB00624 | DB00631 | 1,561 | 372 | [
"DDInter1775",
"DDInter405"
] | Testosterone | Clofarabine | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Moderate | 1 | [
[
[
1561,
24,
372
]
],
[
[
1561,
6,
17404
],
[
17404,
45,
372
]
],
[
[
1561,
7,
13230
],
[
13230,
46,
372
]
],
[
[
1561,
18,
7039
],
[
703... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
]
],
[
[
"Testosterone",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound... | Testosterone (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Clofarabine (Compound)
Testosterone (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Clofarabine (Compound)
Testosterone (Compound) downregulates TLE1 (Gene) and TLE1 (Gene) is downregulated by Clofarabine (Compound)
Testost... |
DB00448 | DB12010 | 1,215 | 214 | [
"DDInter1022",
"DDInter785"
] | Lansoprazole | Fostamatinib | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1215,
24,
214
]
],
[
[
1215,
24,
976
],
[
976,
24,
214
]
],
[
[
1215,
25,
1250
],
[
1250,
24,
214
]
],
[
[
1215,
63,
600
],
[
600,
... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
... | Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Lansoprazole may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may ... |
DB11793 | DB11978 | 738 | 124 | [
"DDInter1297",
"DDInter822"
] | Niraparib | Glasdegib | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
738,
24,
124
]
],
[
[
738,
24,
466
],
[
466,
62,
124
]
],
[
[
738,
24,
829
],
[
829,
63,
124
]
],
[
[
738,
24,
1612
],
[
1612,
2... | [
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant and Ubrogep... |
DB00425 | DB00792 | 558 | 832 | [
"DDInter1970",
"DDInter1878"
] | Zolpidem | Tripelennamine | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
558,
24,
832
]
],
[
[
558,
24,
100
],
[
100,
63,
832
]
],
[
[
558,
24,
649
],
[
649,
1,
832
]
],
[
[
558,
63,
1594
],
[
1594,
24... | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
... | Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol ... |
DB00254 | DB01125 | 964 | 279 | [
"DDInter598",
"DDInter98"
] | Doxycycline | Anisindione | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Moderate | 1 | [
[
[
964,
24,
279
]
],
[
[
964,
24,
319
],
[
319,
24,
279
]
],
[
[
964,
63,
1595
],
[
1595,
24,
279
]
],
[
[
964,
1,
1572
],
[
1572,
... | [
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxicillin"
],
... | Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Amoxicillin and Amoxicillin may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clos... |
DB01144 | DB01278 | 1,326 | 1,021 | [
"DDInter540",
"DDInter1506"
] | Diclofenamide | Pramlintide | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
1326,
24,
1021
]
],
[
[
1326,
24,
708
],
[
708,
63,
1021
]
],
[
[
1326,
63,
891
],
[
891,
24,
1021
]
],
[
[
1326,
40,
504
],
[
504,
... | [
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]... | Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin and Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Predniso... |
DB00418 | DB00603 | 536 | 303 | [
"DDInter1650",
"DDInter1137"
] | Secobarbital | Medroxyprogesterone acetate | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Moderate | 1 | [
[
[
536,
24,
303
]
],
[
[
536,
24,
167
],
[
167,
1,
303
]
],
[
[
536,
6,
6017
],
[
6017,
45,
303
]
],
[
[
536,
21,
29081
],
[
29081,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroc... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Medroxyprogesterone acetate (Compound)
Secobarbital (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Medroxyprogesterone acetate (Compound)
Secobarbital (Compou... |
DB00400 | DB00673 | 353 | 723 | [
"DDInter843",
"DDInter112"
] | Griseofulvin | Aprepitant | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
353,
24,
723
]
],
[
[
353,
24,
875
],
[
875,
40,
723
]
],
[
[
353,
6,
7950
],
[
7950,
45,
723
]
],
[
[
353,
21,
28698
],
[
28698,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant (Compound) resembles Aprepitant (Compound)
Griseofulvin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Aprepitant (Compound)
Griseofulvin (Compound) causes Insomnia (Side Effect) an... |
DB00342 | DB00938 | 1,181 | 455 | [
"DDInter1770",
"DDInter1635"
] | Terfenadine | Salmeterol | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
1181,
24,
455
]
],
[
[
1181,
24,
688
],
[
688,
63,
455
]
],
[
[
1181,
25,
1568
],
[
1568,
63,
455
]
],
[
[
1181,
24,
1262
],
[
1262,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Terfenadine may lead to a major life threatening interaction when taken with Pimozide and Pimozide may cause a ... |
DB00252 | DB11828 | 362 | 1,406 | [
"DDInter1460",
"DDInter1281"
] | Phenytoin | Neratinib | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Major | 2 | [
[
[
362,
25,
1406
]
],
[
[
362,
25,
1135
],
[
1135,
23,
1406
]
],
[
[
362,
24,
392
],
[
392,
24,
1406
]
],
[
[
362,
25,
1510
],
[
1510,
... | [
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may ca... | Phenytoin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderat... |
DB00226 | DB01067 | 1,000 | 959 | [
"DDInter845",
"DDInter826"
] | Guanadrel | Glipizide | Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1000,
24,
959
]
],
[
[
1000,
63,
245
],
[
245,
40,
959
]
],
[
[
1000,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1000,
24,
22
],
[
22,
... | [
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
... |
DB00819 | DB01169 | 471 | 57 | [
"DDInter15",
"DDInter120"
] | Acetazolamide | Arsenic trioxide | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
471,
25,
57
]
],
[
[
471,
6,
8374
],
[
8374,
45,
57
]
],
[
[
471,
24,
603
],
[
603,
63,
57
]
],
[
[
471,
24,
480
],
[
480,
24,
... | [
[
[
"Acetazolamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Acetazolamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Acetazolamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Arsenic trioxide (Compound)
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Ars... |
DB00679 | DB01067 | 684 | 959 | [
"DDInter1796",
"DDInter826"
] | Thioridazine | Glipizide | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
684,
24,
959
]
],
[
[
684,
63,
245
],
[
245,
40,
959
]
],
[
[
684,
24,
1411
],
[
1411,
1,
959
]
],
[
[
684,
7,
4789
],
[
4789,
4... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Comp... |
DB00687 | DB00808 | 870 | 1,605 | [
"DDInter747",
"DDInter916"
] | Fludrocortisone | Indapamide | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Moderate | 1 | [
[
[
870,
24,
1605
]
],
[
[
870,
63,
811
],
[
811,
1,
1605
]
],
[
[
870,
24,
1335
],
[
1335,
40,
1605
]
],
[
[
870,
21,
29644
],
[
29644,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
]... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Indapa... |
DB00497 | DB00758 | 828 | 1,347 | [
"DDInter1366",
"DDInter413"
] | Oxycodone | Clopidogrel | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Moderate | 1 | [
[
[
828,
24,
1347
]
],
[
[
828,
6,
7524
],
[
7524,
45,
1347
]
],
[
[
828,
21,
29402
],
[
29402,
60,
1347
]
],
[
[
828,
24,
522
],
[
522,
... | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Oxycodone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
... | Oxycodone (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Clopidogrel (Compound)
Oxycodone (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Clopidogrel (Compound)
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken w... |
DB05316 | DB08868 | 749 | 1,011 | [
"DDInter1467",
"DDInter737"
] | Pimavanserin | Fingolimod | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
749,
25,
1011
]
],
[
[
749,
24,
578
],
[
578,
23,
1011
]
],
[
[
749,
62,
112
],
[
112,
23,
1011
]
],
[
[
749,
24,
144
],
[
144,
... | [
[
[
"Pimavanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagr... | Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Pimavanserin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Met... |
DB01165 | DB08875 | 1,539 | 1,618 | [
"DDInter1325",
"DDInter262"
] | Ofloxacin | Cabozantinib | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1539,
25,
1618
]
],
[
[
1539,
62,
112
],
[
112,
23,
1618
]
],
[
[
1539,
63,
480
],
[
480,
24,
1618
]
],
[
[
1539,
24,
170
],
[
170,
... | [
[
[
"Ofloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Ofloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Form... |
DB00288 | DB09043 | 1,103 | 135 | [
"DDInter63",
"DDInter36"
] | Amcinonide | Albiglutide | Amcinonide is a corticosteroid. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Minor | 0 | [
[
[
1103,
23,
135
]
],
[
[
1103,
62,
1647
],
[
1647,
23,
135
]
],
[
[
1103,
40,
870
],
[
870,
24,
135
]
],
[
[
1103,
62,
176
],
[
176,
... | [
[
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Albiglutide"
]
],
[
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acarbose"
],
[
"... | Amcinonide may cause a minor interaction that can limit clinical effects when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Amcinonide (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that co... |
DB00361 | DB11718 | 134 | 927 | [
"DDInter1939",
"DDInter640"
] | Vinorelbine | Encorafenib | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
134,
24,
927
]
],
[
[
134,
24,
112
],
[
112,
23,
927
]
],
[
[
134,
24,
372
],
[
372,
24,
927
]
],
[
[
134,
25,
770
],
[
770,
24,... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine an... |
DB01004 | DB06810 | 563 | 397 | [
"DDInter806",
"DDInter1484"
] | Ganciclovir | Plicamycin | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Moderate | 1 | [
[
[
563,
24,
397
]
],
[
[
563,
63,
597
],
[
597,
24,
397
]
],
[
[
563,
1,
248
],
[
248,
24,
397
]
],
[
[
563,
24,
384
],
[
384,
63,
... | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plicamycin"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
... | Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Ganciclovir (Compound) resembles Valganciclovir (Compound) and Val
Ganciclovir may cause a moderate i... |
DB00222 | DB06335 | 245 | 761 | [
"DDInter825",
"DDInter1646"
] | Glimepiride | Saxagliptin | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
245,
24,
761
]
],
[
[
245,
21,
28722
],
[
28722,
60,
761
]
],
[
[
245,
23,
1103
],
[
1103,
23,
761
]
],
[
[
245,
24,
1491
],
[
1491,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Glimepiride",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused ... | Glimepiride (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Saxagliptin (Compound)
Glimepiride may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Saxagliptin
Gl... |
DB01174 | DB08896 | 697 | 292 | [
"DDInter1442",
"DDInter1576"
] | Phenobarbital | Regorafenib | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
697,
24,
292
]
],
[
[
697,
63,
79
],
[
79,
1,
292
]
],
[
[
697,
6,
6017
],
[
6017,
45,
292
]
],
[
[
697,
21,
28658
],
[
28658,
6... | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
... | Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Regorafenib (Compound)
Phenobarbital (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Phenobarbital (Compound) causes Vomiting (Side Effect) and V... |
DB01218 | DB09472 | 1,493 | 1,383 | [
"DDInter852",
"DDInter1693"
] | Halofantrine | Sodium sulfate | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Major | 2 | [
[
[
1493,
25,
1383
]
],
[
[
1493,
64,
609
],
[
609,
24,
1383
]
],
[
[
1493,
25,
1342
],
[
1342,
24,
1383
]
],
[
[
1493,
25,
1612
],
[
1612... | [
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromyci... | Halofantrine may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Halofantrine may lead to a major life threatening interaction when taken with Romidepsin and Romidepsin may cause... |
DB00047 | DB00220 | 176 | 798 | [
"DDInter932",
"DDInter1276"
] | Insulin glargine | Nelfinavir | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Moderate | 1 | [
[
[
176,
24,
798
]
],
[
[
176,
24,
215
],
[
215,
40,
798
]
],
[
[
176,
24,
1327
],
[
1327,
1,
798
]
],
[
[
176,
24,
222
],
[
222,
62... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nelfinavir"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indinavir"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Indinavir and Indinavir (Compound) resembles Nelfinavir (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) resembles Nelfinavir (... |
DB06822 | DB11793 | 802 | 738 | [
"DDInter1812",
"DDInter1297"
] | Tinzaparin | Niraparib | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
802,
24,
738
]
],
[
[
802,
64,
1213
],
[
1213,
24,
738
]
],
[
[
802,
63,
443
],
[
443,
24,
738
]
],
[
[
802,
25,
578
],
[
578,
2... | [
[
[
"Tinzaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Tinzaparin may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Spironolactone and Spironolactone may c... |
DB00701 | DB01098 | 1,091 | 14 | [
"DDInter90",
"DDInter1622"
] | Amprenavir | Rosuvastatin | Amprenavir is a protease inhibitor used to treat HIV infection. | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Major | 2 | [
[
[
1091,
25,
14
]
],
[
[
1091,
6,
10417
],
[
10417,
45,
14
]
],
[
[
1091,
21,
29052
],
[
29052,
60,
14
]
],
[
[
1091,
62,
600
],
[
600,
... | [
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Amprenavir",
"{u} (Compound) binds {v} (Gene)",
"ABCC1"
],
[
"ABCC1",
"{u} (Gene) is bound by {v} (Compound)",
"Rosuvas... | Amprenavir (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Rosuvastatin (Compound)
Amprenavir (Compound) causes Sleep disorder (Side Effect) and Sleep disorder (Side Effect) is caused by Rosuvastatin (Compound)
Amprenavir may cause a minor interaction that can limit clinical effects when taken with Fluconazo... |
DB00700 | DB11827 | 312 | 433 | [
"DDInter656",
"DDInter669"
] | Eplerenone | Ertugliflozin | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone c... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
312,
24,
433
]
],
[
[
312,
63,
251
],
[
251,
24,
433
]
],
[
[
312,
74,
870
],
[
870,
24,
433
]
],
[
[
312,
24,
820
],
[
820,
24,... | [
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
... | Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Eplerenone (Compound) resembles Fludrocortisone (Compound) and Eplerenone may cause a moderate interact... |
DB00682 | DB01105 | 126 | 222 | [
"DDInter1951",
"DDInter1665"
] | Warfarin | Sibutramine | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
126,
24,
222
]
],
[
[
126,
6,
8374
],
[
8374,
45,
222
]
],
[
[
126,
7,
2384
],
[
2384,
46,
222
]
],
[
[
126,
64,
839
],
[
839,
2... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Warfarin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Warfarin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Warfarin (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Sibutramine (Compound)
Warfarin may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a minor in... |
DB06822 | DB09079 | 802 | 1,496 | [
"DDInter1812",
"DDInter1296"
] | Tinzaparin | Nintedanib | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
802,
24,
1496
]
],
[
[
802,
64,
20
],
[
20,
24,
1496
]
],
[
[
802,
24,
1412
],
[
1412,
63,
1496
]
],
[
[
802,
25,
840
],
[
840,
... | [
[
[
"Tinzaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenectep... | Tinzaparin may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calasparg... |
DB00440 | DB13620 | 1,548 | 948 | [
"DDInter1874",
"DDInter1499"
] | Trimethoprim | Potassium gluconate | Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in comb... | Potassium gluconate is a salt of and is classified as a food additive by the FDA . It is also used as a potassium supplement . Potassium is an essential nutrient. It is the most abundant cation in the intracellular fluid, where it plays a key role in maintaining cell function . In dietary supplements, potassium is ofte... | Major | 2 | [
[
[
1548,
25,
948
]
],
[
[
1548,
25,
554
],
[
554,
62,
176
],
[
176,
23,
948
]
],
[
[
1548,
63,
1645
],
[
1645,
63,
176
],
[
176,
23,
... | [
[
[
"Trimethoprim",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium gluconate"
]
],
[
[
"Trimethoprim",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium perchlorate"
],
[
"P... | Trimethoprim may lead to a major life threatening interaction when taken with Potassium perchlorate and Potassium perchlorate may cause a minor interaction that can limit clinical effects when taken with Insulin glargine and Insulin glargine may cause a minor interaction that can limit clinical effects when taken with ... |
DB00115 | DB00501 | 227 | 752 | [
"DDInter451",
"DDInter380"
] | Cyanocobalamin | Cimetidine | Cyanocobalamin (commonly known as Vitamin B12) is a highly complex, essential vitamin, owing its name to the fact that it contains the mineral, cobalt. This vitamin is produced naturally by bacteria, and is necessary for DNA synthesis and cellular energy production. Vitamin B12 has many forms, including the cyano-, met... | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Minor | 0 | [
[
[
227,
23,
752
]
],
[
[
227,
1,
204
],
[
204,
21,
28741
],
[
28741,
60,
752
]
],
[
[
227,
6,
17356
],
[
17356,
46,
461
],
[
461,
24,
... | [
[
[
"Cyanocobalamin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
]
],
[
[
"Cyanocobalamin",
"{u} (Compound) resembles {v} (Compound)",
"Hydroxocobalamin"
],
[
"Hydroxocobalamin",
"{u} (... | Cyanocobalamin (Compound) resembles Hydroxocobalamin (Compound) and Hydroxocobalamin (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Cimetidine (Compound)
Cyanocobalamin (Compound) binds TCN1 (Gene) and TCN1 (Gene) is upregulated by Timolol (Compound) and Timolol may cause a moderate ... |
DB01403 | DB06691 | 9 | 849 | [
"DDInter1175",
"DDInter1155"
] | Methotrimeprazine | Mepyramine | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
9,
35,
849
]
],
[
[
9,
63,
1594
],
[
1594,
24,
849
]
],
[
[
9,
1,
324
],
[
324,
40,
849
]
],
[
[
9,
6,
12523
],
[
12523,
45,
... | [
[
[
"Methotrimeprazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate disease... | Methotrimeprazine (Compound) resembles Mepyramine (Compound) and
Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Methotrimeprazine (Compound) resembles D... |
DB05773 | DB08903 | 1,047 | 996 | [
"DDInter1848",
"DDInter170"
] | Trastuzumab emtansine | Bedaquiline | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affe... | Moderate | 1 | [
[
[
1047,
24,
996
]
],
[
[
1047,
63,
112
],
[
112,
23,
996
]
],
[
[
1047,
63,
848
],
[
848,
24,
996
]
],
[
[
1047,
24,
350
],
[
350,
... | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metr... | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bedaquiline
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken... |
DB00819 | DB01001 | 471 | 688 | [
"DDInter15",
"DDInter1632"
] | Acetazolamide | Salbutamol | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
471,
24,
688
]
],
[
[
471,
24,
455
],
[
455,
24,
688
]
],
[
[
471,
6,
8374
],
[
8374,
45,
688
]
],
[
[
471,
21,
28714
],
[
28714,
... | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
... | Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Acetazolamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Salbutamol (Compound)
Acetazolamid... |
DB01359 | DB08865 | 729 | 1,593 | [
"DDInter1417",
"DDInter448"
] | Penbutolol | Crizotinib | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
729,
24,
1593
]
],
[
[
729,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
729,
23,
286
],
[
286,
63,
1593
]
],
[
[
729,
64,
455
],
[
455,
... | [
[
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Penbutolol",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused b... | Penbutolol (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Penbutolol may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00388 | DB14509 | 1,636 | 1,399 | [
"DDInter1453",
"DDInter1081"
] | Phenylephrine | Lithium carbonate | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Minor | 0 | [
[
[
1636,
23,
1399
]
],
[
[
1636,
1,
874
],
[
874,
23,
1399
]
],
[
[
1636,
24,
1385
],
[
1385,
24,
1399
]
],
[
[
1636,
63,
1645
],
[
1645,... | [
[
[
"Phenylephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Phenylephrine",
"{u} (Compound) resembles {v} (Compound)",
"Epinephrine"
],
[
"Epinephrine",
"{u} may ca... | Phenylephrine (Compound) resembles Epinephrine (Compound) and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interac... |
DB00081 | DB00586 | 273 | 1,512 | [
"DDInter1838",
"DDInter537"
] | Tositumomab | Diclofenac | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Major | 2 | [
[
[
273,
25,
1512
]
],
[
[
273,
24,
282
],
[
282,
40,
1512
]
],
[
[
273,
24,
1263
],
[
1263,
63,
1512
]
],
[
[
273,
25,
885
],
[
885,
... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diclofenac"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nepafenac"
],
[
"Nepafenac... | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Nepafenac and Nepafenac (Compound) resembles Diclofenac (Compound)
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Bromfenac may cause a moderate interaction that could e... |
DB01253 | DB09065 | 628 | 760 | [
"DDInter664",
"DDInter424"
] | Ergometrine | Cobicistat | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
628,
25,
760
]
],
[
[
628,
63,
1101
],
[
1101,
23,
760
]
],
[
[
628,
24,
1374
],
[
1374,
23,
760
]
],
[
[
628,
63,
723
],
[
723,
... | [
[
[
"Ergometrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Ergometrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarote... | Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abira... |
DB00421 | DB01050 | 443 | 848 | [
"DDInter1707",
"DDInter900"
] | Spironolactone | Ibuprofen | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
443,
24,
848
]
],
[
[
443,
24,
1053
],
[
1053,
1,
848
]
],
[
[
443,
6,
6648
],
[
6648,
45,
848
]
],
[
[
443,
21,
28929
],
[
28929,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine (Compound) resembles Ibuprofen (Compound)
Spironolactone (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Ibuprofen (Compound)
Spironolactone (Compound) causes Confusional state (Si... |
DB09048 | DB11691 | 555 | 1,499 | [
"DDInter1284",
"DDInter1258"
] | Netupitant | Naldemedine | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
555,
24,
1499
]
],
[
[
555,
63,
723
],
[
723,
24,
1499
]
],
[
[
555,
64,
1670
],
[
1670,
24,
1499
]
],
[
[
555,
25,
1406
],
[
1406,
... | [
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Netupitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Netupitant may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Netupitant may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause... |
DB01203 | DB09564 | 699 | 1,296 | [
"DDInter1255",
"DDInter930"
] | Nadolol | Insulin degludec | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
699,
24,
1296
]
],
[
[
699,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
699,
25,
659
],
[
659,
24,
1296
]
],
[
[
699,
24,
1151
],
[
1151,
... | [
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
... | Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Nadolol may lead to a major life threatening interaction when taken with Vilanterol and Vilanterol may caus... |
DB00848 | DB01097 | 281 | 1,377 | [
"DDInter1044",
"DDInter1033"
] | Levamisole | Leflunomide | Levamisole is an antihelminthic drug that was commonly used for the treatment of parasitic, viral, and bacterial infections. It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. Prior to this,... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
281,
25,
1377
]
],
[
[
281,
24,
949
],
[
949,
63,
1377
]
],
[
[
281,
63,
126
],
[
126,
24,
1377
]
],
[
[
281,
24,
563
],
[
563,
... | [
[
[
"Levamisole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Levamisole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formal... | Levamisole may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Levamisole ... |
DB05316 | DB08816 | 749 | 578 | [
"DDInter1467",
"DDInter1802"
] | Pimavanserin | Ticagrelor | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Moderate | 1 | [
[
[
749,
24,
578
]
],
[
[
749,
25,
1011
],
[
1011,
62,
578
]
],
[
[
749,
63,
723
],
[
723,
24,
578
]
],
[
[
749,
25,
868
],
[
868,
6... | [
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
]
],
[
[
"Pimavanserin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingol... | Pimavanserin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may caus... |
DB00047 | DB01324 | 176 | 178 | [
"DDInter932",
"DDInter1490"
] | Insulin glargine | Polythiazide | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Moderate | 1 | [
[
[
176,
24,
178
]
],
[
[
176,
24,
674
],
[
674,
40,
178
]
],
[
[
176,
24,
964
],
[
964,
23,
178
]
],
[
[
176,
24,
52
],
[
52,
63,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethi... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Trichlormethiazide and Trichlormethiazide (Compound) resembles Polythiazide (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a... |
DB00016 | DB00519 | 787 | 1,638 | [
"DDInter671",
"DDInter1843"
] | Erythropoietin | Trandolapril | Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label]. Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commerc... | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Minor | 0 | [
[
[
787,
23,
1638
]
],
[
[
787,
23,
954
],
[
954,
40,
1638
]
],
[
[
787,
23,
954
],
[
954,
40,
1058
],
[
1058,
40,
1638
]
],
[
[
787,
... | [
[
[
"Erythropoietin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trandolapril"
]
],
[
[
"Erythropoietin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinapril"
],
... | Erythropoietin may cause a minor interaction that can limit clinical effects when taken with Quinapril and Quinapril (Compound) resembles Trandolapril (Compound)
Erythropoietin may cause a minor interaction that can limit clinical effects when taken with Quinapril and Quinapril (Compound) resembles Moexipril (Compound)... |
DB00108 | DB06595 | 1,066 | 1,491 | [
"DDInter1268",
"DDInter1214"
] | Natalizumab | Midostaurin | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
1066,
25,
1491
]
],
[
[
1066,
64,
58
],
[
58,
24,
1491
]
],
[
[
1066,
25,
270
],
[
270,
63,
1491
]
],
[
[
1066,
25,
1342
],
[
1342,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} ... | Natalizumab may lead to a major life threatening interaction when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Natalizumab may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate i... |
DB01098 | DB09276 | 14 | 381 | [
"DDInter1622",
"DDInter1682"
] | Rosuvastatin | Sodium aurothiomalate | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no valu... | Moderate | 1 | [
[
[
14,
24,
381
]
],
[
[
14,
63,
491
],
[
491,
24,
381
]
],
[
[
14,
24,
1047
],
[
1047,
24,
381
]
],
[
[
14,
24,
1480
],
[
1480,
63,... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterfero... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Rosuvastatin may cause a moderate interaction that could exacerbate diseases ... |
DB01044 | DB01156 | 246 | 593 | [
"DDInter809",
"DDInter252"
] | Gatifloxacin | Bupropion | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatiflox... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
246,
25,
593
]
],
[
[
246,
7,
3677
],
[
3677,
46,
593
]
],
[
[
246,
18,
4930
],
[
4930,
57,
593
]
],
[
[
246,
21,
28757
],
[
28757,
... | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) upregulates {v} (Gene)",
"NFKBIE"
],
[
"NFKBIE",
"{u} (Gene) is upregulated by {v} (Compound)",... | Gatifloxacin (Compound) upregulates NFKBIE (Gene) and NFKBIE (Gene) is upregulated by Bupropion (Compound)
Gatifloxacin (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Bupropion (Compound)
Gatifloxacin (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Bupropion (C... |
DB00564 | DB00959 | 1,236 | 1,486 | [
"DDInter293",
"DDInter1191"
] | Carbamazepine | Methylprednisolone | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
1236,
24,
1486
]
],
[
[
1236,
24,
175
],
[
175,
40,
1486
]
],
[
[
1236,
24,
167
],
[
167,
1,
1486
]
],
[
[
1236,
63,
251
],
[
251,
... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone... | Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) rese... |
DB00377 | DB09068 | 1,494 | 1,427 | [
"DDInter1382",
"DDInter1948"
] | Palonosetron | Vortioxetine | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Major | 2 | [
[
[
1494,
25,
1427
]
],
[
[
1494,
24,
477
],
[
477,
24,
1427
]
],
[
[
1494,
24,
971
],
[
971,
63,
1427
]
],
[
[
1494,
64,
702
],
[
702,
... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vortioxetine"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilo... | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib an... |
DB00794 | DB09030 | 759 | 840 | [
"DDInter1521",
"DDInter1945"
] | Primidone | Vorapaxar | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
759,
25,
840
]
],
[
[
759,
25,
765
],
[
765,
24,
840
]
],
[
[
759,
25,
1017
],
[
1017,
63,
840
]
],
[
[
759,
24,
222
],
[
222,
2... | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hemin"
],
[
"Hemin",
"{u} may cause a mo... | Primidone may lead to a major life threatening interaction when taken with Hemin and Hemin may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Primidone may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that ... |
DB00960 | DB09133 | 887 | 1,527 | [
"DDInter1471",
"DDInter965"
] | Pindolol | Iothalamic acid | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. | Moderate | 1 | [
[
[
887,
24,
1527
]
],
[
[
887,
24,
278
],
[
278,
63,
1527
]
],
[
[
887,
24,
512
],
[
512,
24,
1527
]
],
[
[
887,
1,
668
],
[
668,
2... | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
],
[... | Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodic acid may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Iopanoic acid an... |
DB00163 | DB01225 | 1,461 | 500 | [
"DDInter1943",
"DDInter645"
] | Vitamin E | Enoxaparin | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Moderate | 1 | [
[
[
1461,
24,
500
]
],
[
[
1461,
24,
298
],
[
298,
63,
500
]
],
[
[
1461,
24,
1317
],
[
1317,
25,
500
]
],
[
[
1461,
24,
840
],
[
840,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxaparin"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Protein C and Protein C may cause a moderate interaction that could exacerbate diseases when taken with Enoxaparin
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyrida... |
DB01064 | DB06706 | 1,148 | 468 | [
"DDInter987",
"DDInter985"
] | Isoprenaline | Isometheptene | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Moderate | 1 | [
[
[
1148,
24,
468
]
],
[
[
1148,
63,
1000
],
[
1000,
24,
468
]
],
[
[
1148,
24,
1340
],
[
1340,
24,
468
]
],
[
[
1148,
74,
1674
],
[
1674,... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanadrel"
],
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel and Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Deserpidine and ... |
DB00241 | DB00860 | 288 | 891 | [
"DDInter257",
"DDInter1513"
] | Butalbital | Prednisolone | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Moderate | 1 | [
[
[
288,
24,
891
]
],
[
[
288,
24,
175
],
[
175,
40,
891
]
],
[
[
288,
24,
1547
],
[
1547,
1,
891
]
],
[
[
288,
24,
384
],
[
384,
63... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisolone (Compound)
Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Exemestane and Exemestane (Compound) resembles Prednisolone (... |
DB00069 | DB06643 | 367 | 1,136 | [
"DDInter946",
"DDInter500"
] | Interferon alfacon-1 | Denosumab | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
367,
24,
1136
]
],
[
[
367,
24,
1555
],
[
1555,
24,
1136
]
],
[
[
367,
64,
1648
],
[
1648,
24,
1136
]
],
[
[
367,
24,
1480
],
[
1480,
... | [
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Interferon alfacon-1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxalipla... | Interferon alfacon-1 may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Interferon alfacon-1 may lead to a major life threatening interaction when taken with Aldesleukin and... |
DB01319 | DB01410 | 34 | 423 | [
"DDInter777",
"DDInter375"
] | Fosamprenavir | Ciclesonide | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco. | Moderate | 1 | [
[
[
34,
24,
423
]
],
[
[
34,
63,
1573
],
[
1573,
1,
423
]
],
[
[
34,
63,
1351
],
[
1351,
40,
423
]
],
[
[
34,
64,
1486
],
[
1486,
40... | [
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ciclesonide"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
... | Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Ciclesonide (Compound)
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Flunisolide and Flunisolide (Compound) resembles Ciclesonide (... |
DB00563 | DB00766 | 663 | 1,675 | [
"DDInter1174",
"DDInter394"
] | Methotrexate | Clavulanic acid | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Clavulanic acid is a beta-lactamase inhibitor that is frequently combined with [Amoxicillin] or [Ticarcillin] to fight antibiotic resistance by preventing their degradation by beta-lactamase enzymes, broadening their spectrum of susceptible bacterial infections. Clavulanic acid is derived from the organism Streptomyces... | Moderate | 1 | [
[
[
663,
24,
1675
]
],
[
[
663,
21,
28931
],
[
28931,
60,
1675
]
],
[
[
663,
24,
850
],
[
850,
63,
1675
]
],
[
[
663,
63,
482
],
[
482,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clavulanic acid"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Haemorrhage"
],
[
"Haemorrhage",
"{u} (Side Ef... | Methotrexate (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Clavulanic acid (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate d... |
DB00047 | DB01319 | 176 | 34 | [
"DDInter932",
"DDInter777"
] | Insulin glargine | Fosamprenavir | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
176,
24,
34
]
],
[
[
176,
24,
1091
],
[
1091,
40,
34
]
],
[
[
176,
24,
609
],
[
609,
23,
34
]
],
[
[
176,
24,
98
],
[
98,
63,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor in... |
DB01100 | DB09098 | 1,568 | 98 | [
"DDInter1470",
"DDInter1700"
] | Pimozide | Somatrem | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1568,
24,
98
]
],
[
[
1568,
25,
159
],
[
159,
63,
98
]
],
[
[
1568,
64,
11
],
[
11,
24,
98
]
],
[
[
1568,
25,
609
],
[
609,
24,
... | [
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib... | Pimozide may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Pimozide may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate inte... |
DB00777 | DB11827 | 146 | 433 | [
"DDInter1537",
"DDInter669"
] | Propiomazine | Ertugliflozin | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Struct... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
146,
24,
433
]
],
[
[
146,
24,
959
],
[
959,
24,
433
]
],
[
[
146,
40,
820
],
[
820,
24,
433
]
],
[
[
146,
63,
274
],
[
274,
24,... | [
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Propiomazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Propiomazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction tha... |
DB04868 | DB11979 | 478 | 1,320 | [
"DDInter1293",
"DDInter625"
] | Nilotinib | Elagolix | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
478,
24,
1320
]
],
[
[
478,
63,
168
],
[
168,
23,
1320
]
],
[
[
478,
23,
271
],
[
271,
23,
1320
]
],
[
[
478,
25,
1612
],
[
1612,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may... |
DB00363 | DB00782 | 695 | 1,123 | [
"DDInter419",
"DDInter1535"
] | Clozapine | Propantheline | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
695,
24,
1123
]
],
[
[
695,
6,
7992
],
[
7992,
45,
1123
]
],
[
[
695,
24,
537
],
[
537,
63,
1123
]
],
[
[
695,
1,
623
],
[
623,
... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"CHRM1"
],
[
"CHRM1",
"{u} (Gene) is bound by {v} (Compound)",
... | Clozapine (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Propantheline (Compound)
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline
Clozapine (Compoun... |
DB01131 | DB01147 | 1,243 | 950 | [
"DDInter1531",
"DDInter418"
] | Proguanil | Cloxacillin | Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. | A semi-synthetic penicillin antibiotic which is a chlorinated derivative of [oxacillin]. | Moderate | 1 | [
[
[
1243,
24,
950
]
],
[
[
1243,
24,
116
],
[
116,
63,
950
]
],
[
[
1243,
63,
126
],
[
126,
24,
950
]
],
[
[
1243,
24,
116
],
[
116,
... | [
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cloxacillin"
]
],
[
[
"Proguanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
],
[
... | Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Cloxacillin
Proguanil may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfa... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.